We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · October 13, 2022

Talimogene Laherparepvec Plus Pembrolizumab for Advanced Melanoma

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
J. Clin. Oncol 2022 Aug 23;[EPub Ahead of Print], JA Chesney, A Ribas, GV Long, JM Kirkwood, R Dummer, I Puzanov, C Hoeller, TF Gajewski, R Gutzmer, P Rutkowski, L Demidov, P Arenberger, SJ Shin, PF Ferrucci, A Haydon, J Hyngstrom, JV van Thienen, S Haferkamp, JM Guilera, BL Rapoport, A VanderWalde, SJ Diede, JR Anderson, S Treichel, EL Chan, S Bhatta, J Gansert, FS Hodi, H Gogas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading